Novo Nordisk is a global pharmaceutical company and the world leader in diabetes and obesity care, supplying roughly half of the world's insulin. Its GLP-1 medicines, semaglutide marketed as Ozempic and oral Rybelsus for type 2 diabetes and Wegovy for obesity, transformed the treatment of metabolic disease and drove years of exceptional growth, with next-generation candidates including CagriSema in development. The company also holds leading positions in rare endocrine disorders and hemophilia through its rare disease segment. Novo Nordisk invests heavily in manufacturing capacity expansion to meet GLP-1 demand, including major fill-finish acquisitions. Founded in 1923 and headquartered in Bagsvaerd, Denmark, it is controlled by the Novo Nordisk Foundation; sales span roughly 170 countries, with the United States its largest market. Its ADRs trade on the NYSE.

Beneish M-Score

Operating Margin %

Novo Nordisk AS 🇩🇰